Condition 1: Osteoporosis. Condition 2: Kyphosis. Postmenopausal osteoporosis Postural kyphosis
Conditions
Interventions
Intervention 1: Case group: A 600000 unit intramuscular vitamin D will be administered. A dose of 35 mg/ week oral Alendronate (Ostomeod, Modava Company, Iran) will also be administered as the osteopo
Treatment - Devices
Treatment - Drugs
Case group: A 600000 unit intramuscular vitamin D will be administered. A dose of 35 mg/ week oral Alendronate (Ostomeod, Modava Company, Iran) will also be administered as the osteoporosis drug of ch
Control group: A 600000 unit intramuscular vitamin D will be administered. A dose of 35 mg/ week oral Alendronate (Ostomeod, Modava Company, Iran) will also be administered as the osteoporosis drug of
Sponsors
Vice chancellor for research, Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: Female; postmenopausal; osteoporosis; Kyphosis; Exclusion criteria: Patients having metabolic or hormonal disorders affecting the skeletal structure; patients receiving drugs with known affect on bone metabolism; patients currently receiving osteoporosis treatment; patients not able to use brace;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Osteoporosis. Timepoint: At the start of the study and one year after the start of the intervention. Method of measurement: Bone mineral density.;Kyphosis. Timepoint: At the start of the study and one year after the start of the intervention. Method of measurement: Ruler. | — |
Secondary
| Measure | Time frame |
|---|---|
| -. Timepoint: -. Method of measurement: -. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Mirzaei
Bone & Joint Reconstraction Research Center
Outcome results
None listed